are our inspiration
Home / People / NOMIS Researcher / Jacob Corn

Jacob Corn

Jacob Corn


NOMIS Project(s)

Jacob Corn is the Professor of Genome Biology at ETH Zurich (Zurich, Switzerland). In addition to the professorship, he is leading the Unbiased Discovery of Heterogeneous DNA Repair Preferences project.

Corn earned a BS in biology from the University of Puget Sound (Tacoma, US) in 2001 and a PhD in molecular and cell biology from the University of California, Berkeley (UC Berkeley; US) in 2007. His career has bridged academia and industry, working in therapeutic areas that include infectious disease, neurobiology, and oncology. Corn’s graduate studies at UC Berkeley with James Berger redefined our understanding of the geometry of DNA replication and was recognized with several honors, including the Nicholas Cozzarelli and Harold Weintraub awards. His work as a Jane Coffin Childs postdoctoral fellow at the University of Washington culminated in the world’s first computationally designed de novo protein interaction and a protein-based inhibitor to treat flu. Corn began his independent research career as a group leader at Genentech, where his lab discovered biological mechanisms for challenging therapeutic targets. He then moved back to academia as the founding scientific director of the Innovative Genomics Institute and faculty at UC Berkeley.

Corn’s research aims to better understand and treat disease through next-generation genome editing technologies. His research takes a multidisciplinary approach, combining cellular biochemistry, functional genomics, computational biology, bioengineering, and biophysics. His lab’s current focus is the development of genome editing, the mechanisms by which cells repair their DNA, and the maintenance of healthy organelles.

Jacob Corn | Awards Film

Jacob Corn | Insights Film

Jacob Corn's News

According to Professor Jacob Corn, we are standing on the threshold of major medical breakthroughs: thanks to advances in the field of genome editing, it may be possible in future […]

Personalized medicine is changing the way clinicians approach diagnosis and treatment by tailoring therapy to individual molecular and genetic profiles. While the idea of tailored medical treatment is not new, […]

Jacob Corn's Insights

Abstract: Genome editing technologies generate targeted DNA lesions and rely on cellular DNA repair pathways for resolution. Understanding the DNA repair mechanisms responsible for resolving the specific damage caused by gene editing tools can significantly advance their optimization and facilitate their broader application in research and therapeutic contexts. Here we explore
Abstract: The β-hemoglobinopathies, such as sickle cell disease and β-thalassemia, are one of the most common genetic diseases worldwide and are caused by mutations affecting the structure or production of β-globin subunits in adult hemoglobin. Many gene editing efforts to treat the β-he-moglobinopathies attempt to correct β-globin mutations or increase γ-globin
Abstract: Macroautophagy is one of two major degradation systems in eukaryotic cells. Regulation and control of autophagy are often achieved through the presence of short peptide sequences called LC3 interacting regions (LIR) in autophagy-involved proteins. Using a combination of new protein-derived activity-based probes prepared from recombinant LC3 proteins, along with protein

Autophagy is a fundamental pathway for the degradation of cytoplasmic content in response to pleiotropic extracellular and intracellular stimuli. Recent advances in the autophagy field have demonstrated that different organelles […]